雅虎香港財經 Insulet Posts Q2 Revenue Beat, Lifts FY22 Guidance
Insulet Corporation (NASDAQ: PODD) posted a Q2 net loss of $(35) million, or an EPS loss of $(0.50) compared to $(0.37) a year ago.
Q2 sales increased 13.8% Y/Y, or 17.7% in constant currency, to $299.4 million, exceeding the guidance range of 12%-15% in constant currency and the consensus of $291.45 million.
Total Omnipod automated insulin delivery system revenue was $285.8 million, +18.1%.
Sales for Omnipod in the U.S. totaled $196.4 million, representing an increase of 30.5%.
Earlier this week, the company announced the full market launch of the latest-generation Omnipod 5 device in U.S. pharmacies.
Guidance: Insulet raised its FY22 revenue growth guidance to 14% - 17% from 12% - 16%.
The company expects growth for Omnipod sales of 18%-21% from 16% - 20% expected earlier.
For Q3, the forecasts sales growth of 17% - 20%, with Omnipod growth of 18% - 21%.
Analyst Reaction: Piper Sandler and Raymond James maintain Neutral and Outperform on Insulet, with the price target raised to $235 from $230 and $280 from $262, respectively.
Price Action: PODD shares closed 0.78% higher at $258.00 during after-hours trading on Thursday.
Latest Ratings for PODD
Date | Firm | Action | From | To |
|---|---|---|---|---|
Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | |
Feb 2022 | Raymond James | Maintains | Outperform | |
Feb 2022 | Piper Sandler | Maintains | Neutral |
View More Analyst Ratings for PODD
View the Latest Analyst Ratings
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
